Joyce Lee
Concepts (354)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lung Diseases, Interstitial | 67 | 2026 | 677 | 12.830 |
Why?
| | Idiopathic Pulmonary Fibrosis | 63 | 2026 | 697 | 11.170 |
Why?
| | Arthritis, Rheumatoid | 26 | 2026 | 1184 | 4.800 |
Why?
| | Scleroderma, Systemic | 10 | 2025 | 123 | 2.400 |
Why?
| | Immunosuppressive Agents | 9 | 2025 | 824 | 2.030 |
Why?
| | Connective Tissue Diseases | 9 | 2021 | 85 | 1.680 |
Why?
| | Cryptogenic Organizing Pneumonia | 2 | 2025 | 20 | 1.620 |
Why?
| | Lung | 28 | 2025 | 4119 | 1.620 |
Why?
| | Mucin-5B | 5 | 2025 | 234 | 1.520 |
Why?
| | Vital Capacity | 19 | 2025 | 293 | 1.500 |
Why?
| | Tomography, X-Ray Computed | 28 | 2025 | 2766 | 1.460 |
Why?
| | Autoimmune Diseases | 11 | 2025 | 466 | 1.460 |
Why?
| | Adrenal Cortex Hormones | 4 | 2025 | 483 | 1.360 |
Why?
| | Disease Progression | 14 | 2025 | 2857 | 1.350 |
Why?
| | Gastroesophageal Reflux | 5 | 2020 | 232 | 1.230 |
Why?
| | Rheumatic Diseases | 5 | 2024 | 101 | 1.170 |
Why?
| | Pulmonary Fibrosis | 10 | 2025 | 395 | 1.140 |
Why?
| | Prognosis | 24 | 2025 | 4331 | 1.120 |
Why?
| | Humans | 136 | 2026 | 145625 | 1.010 |
Why?
| | Myositis | 5 | 2025 | 57 | 0.980 |
Why?
| | Alveolitis, Extrinsic Allergic | 6 | 2022 | 96 | 0.950 |
Why?
| | Respiratory Aspiration | 4 | 2020 | 32 | 0.910 |
Why?
| | Biomarkers | 12 | 2025 | 4329 | 0.880 |
Why?
| | Telomere | 3 | 2025 | 300 | 0.850 |
Why?
| | Aged | 54 | 2026 | 26251 | 0.840 |
Why?
| | Middle Aged | 58 | 2026 | 36359 | 0.840 |
Why?
| | Idiopathic Interstitial Pneumonias | 4 | 2019 | 44 | 0.830 |
Why?
| | Quality of Life | 4 | 2024 | 3187 | 0.800 |
Why?
| | Diagnosis, Differential | 10 | 2025 | 1500 | 0.760 |
Why?
| | Telomerase | 2 | 2023 | 252 | 0.740 |
Why?
| | Carcinoma, Hepatocellular | 5 | 2025 | 369 | 0.740 |
Why?
| | Pulmonary Surfactants | 1 | 2023 | 105 | 0.730 |
Why?
| | Histamine H2 Antagonists | 2 | 2013 | 22 | 0.720 |
Why?
| | Glucocorticoids | 3 | 2024 | 536 | 0.710 |
Why?
| | Matrix Metalloproteinase 7 | 1 | 2021 | 25 | 0.700 |
Why?
| | Proton Pump Inhibitors | 2 | 2013 | 101 | 0.680 |
Why?
| | Respiratory Function Tests | 11 | 2025 | 543 | 0.680 |
Why?
| | Male | 71 | 2026 | 73014 | 0.670 |
Why?
| | Proteomics | 3 | 2025 | 1202 | 0.640 |
Why?
| | Rheumatology | 5 | 2024 | 136 | 0.630 |
Why?
| | Lung Transplantation | 10 | 2025 | 326 | 0.620 |
Why?
| | Female | 70 | 2026 | 79080 | 0.610 |
Why?
| | Cellular Senescence | 1 | 2021 | 225 | 0.560 |
Why?
| | Telomere Shortening | 3 | 2025 | 20 | 0.540 |
Why?
| | Liver Neoplasms | 5 | 2025 | 774 | 0.530 |
Why?
| | Genetic Predisposition to Disease | 3 | 2026 | 2455 | 0.520 |
Why?
| | Prospective Studies | 13 | 2025 | 8087 | 0.510 |
Why?
| | Severity of Illness Index | 10 | 2025 | 2910 | 0.490 |
Why?
| | Abatacept | 3 | 2025 | 56 | 0.490 |
Why?
| | Dyspnea | 5 | 2023 | 251 | 0.470 |
Why?
| | Patient Satisfaction | 2 | 2021 | 698 | 0.470 |
Why?
| | Forecasting | 1 | 2017 | 386 | 0.460 |
Why?
| | Survival Rate | 11 | 2025 | 2078 | 0.460 |
Why?
| | Risk Assessment | 10 | 2021 | 3678 | 0.450 |
Why?
| | Longitudinal Studies | 8 | 2017 | 3005 | 0.400 |
Why?
| | Cohort Studies | 13 | 2025 | 6045 | 0.400 |
Why?
| | Patient Education as Topic | 2 | 2016 | 769 | 0.390 |
Why?
| | Azathioprine | 2 | 2024 | 43 | 0.390 |
Why?
| | Pulmonary Diffusing Capacity | 5 | 2020 | 78 | 0.380 |
Why?
| | Early Diagnosis | 2 | 2025 | 249 | 0.370 |
Why?
| | Precision Medicine | 1 | 2017 | 462 | 0.370 |
Why?
| | Rituximab | 2 | 2024 | 208 | 0.360 |
Why?
| | Hypertension, Pulmonary | 3 | 2022 | 1957 | 0.360 |
Why?
| | Pepsin A | 1 | 2011 | 18 | 0.350 |
Why?
| | Antirheumatic Agents | 4 | 2024 | 309 | 0.340 |
Why?
| | Comprehensive Health Care | 1 | 2011 | 24 | 0.340 |
Why?
| | Fundoplication | 1 | 2011 | 49 | 0.330 |
Why?
| | Sleep Apnea, Obstructive | 1 | 2015 | 300 | 0.330 |
Why?
| | Carbon Monoxide | 4 | 2019 | 82 | 0.310 |
Why?
| | Veterans | 4 | 2023 | 1647 | 0.310 |
Why?
| | Endotoxins | 1 | 2010 | 215 | 0.300 |
Why?
| | Bronchoalveolar Lavage Fluid | 2 | 2011 | 641 | 0.300 |
Why?
| | Forced Expiratory Volume | 4 | 2025 | 451 | 0.300 |
Why?
| | Sirolimus | 1 | 2011 | 282 | 0.300 |
Why?
| | Proportional Hazards Models | 7 | 2024 | 1318 | 0.290 |
Why?
| | Phenotype | 6 | 2025 | 3186 | 0.290 |
Why?
| | Anti-Bacterial Agents | 1 | 2019 | 1935 | 0.280 |
Why?
| | Walk Test | 2 | 2025 | 82 | 0.270 |
Why?
| | United States | 17 | 2025 | 16041 | 0.270 |
Why?
| | Biopsy | 5 | 2025 | 1073 | 0.270 |
Why?
| | Risk Factors | 12 | 2026 | 10840 | 0.270 |
Why?
| | Retrospective Studies | 16 | 2024 | 17291 | 0.260 |
Why?
| | Emphysema | 2 | 2022 | 100 | 0.260 |
Why?
| | Mycophenolic Acid | 3 | 2024 | 117 | 0.260 |
Why?
| | Acute Lung Injury | 1 | 2010 | 311 | 0.250 |
Why?
| | Lung Diseases | 3 | 2020 | 787 | 0.250 |
Why?
| | Comorbidity | 5 | 2015 | 1652 | 0.250 |
Why?
| | Autoantibodies | 2 | 2015 | 1498 | 0.230 |
Why?
| | Prevalence | 5 | 2022 | 2852 | 0.230 |
Why?
| | Cancer-Associated Fibroblasts | 1 | 2025 | 23 | 0.230 |
Why?
| | Immunotherapy | 3 | 2025 | 669 | 0.230 |
Why?
| | Depression | 1 | 2015 | 1566 | 0.230 |
Why?
| | Predictive Value of Tests | 4 | 2017 | 2097 | 0.220 |
Why?
| | Thoracic Surgery, Video-Assisted | 1 | 2025 | 55 | 0.220 |
Why?
| | Pulmonologists | 1 | 2025 | 14 | 0.220 |
Why?
| | Yttrium Radioisotopes | 2 | 2023 | 64 | 0.220 |
Why?
| | Mutation | 3 | 2023 | 4082 | 0.220 |
Why?
| | Pyridones | 2 | 2024 | 210 | 0.220 |
Why?
| | Antineoplastic Agents, Phytogenic | 1 | 2026 | 178 | 0.220 |
Why?
| | Paclitaxel | 1 | 2026 | 258 | 0.220 |
Why?
| | Sex Factors | 4 | 2020 | 2101 | 0.210 |
Why?
| | Aged, 80 and over | 10 | 2024 | 8351 | 0.210 |
Why?
| | Case-Control Studies | 6 | 2021 | 3633 | 0.200 |
Why?
| | Endothelium, Vascular | 1 | 2010 | 952 | 0.200 |
Why?
| | Spirometry | 3 | 2025 | 234 | 0.200 |
Why?
| | Biopsy, Needle | 3 | 2019 | 182 | 0.200 |
Why?
| | Chronic Disease | 6 | 2020 | 1824 | 0.200 |
Why?
| | Pulmonary Emphysema | 2 | 2025 | 276 | 0.190 |
Why?
| | Exercise Tolerance | 1 | 2025 | 288 | 0.190 |
Why?
| | Sputum | 1 | 2025 | 302 | 0.190 |
Why?
| | Blood Proteins | 1 | 2025 | 239 | 0.190 |
Why?
| | Urinary Bladder Neoplasms | 1 | 2026 | 257 | 0.190 |
Why?
| | Fatty Liver | 1 | 2025 | 251 | 0.190 |
Why?
| | Treatment Outcome | 8 | 2025 | 11744 | 0.190 |
Why?
| | Polychlorinated Dibenzodioxins | 1 | 2022 | 10 | 0.190 |
Why?
| | Transforming Growth Factor beta | 1 | 2025 | 466 | 0.180 |
Why?
| | Fibrosis | 3 | 2022 | 568 | 0.180 |
Why?
| | T-Lymphocytes, Regulatory | 1 | 2025 | 411 | 0.180 |
Why?
| | Indoles | 2 | 2024 | 509 | 0.180 |
Why?
| | Recurrence | 1 | 2025 | 1125 | 0.180 |
Why?
| | Genotype | 2 | 2025 | 1866 | 0.180 |
Why?
| | Adult | 19 | 2025 | 40821 | 0.170 |
Why?
| | Genetic Testing | 1 | 2025 | 491 | 0.170 |
Why?
| | Self Care | 2 | 2017 | 396 | 0.170 |
Why?
| | Monocytes | 2 | 2021 | 538 | 0.170 |
Why?
| | Organizational Objectives | 1 | 2021 | 67 | 0.170 |
Why?
| | Incidence | 5 | 2023 | 2910 | 0.170 |
Why?
| | Nursing Research | 1 | 2021 | 49 | 0.160 |
Why?
| | Genetic Markers | 1 | 2022 | 337 | 0.160 |
Why?
| | Societies, Medical | 5 | 2025 | 901 | 0.160 |
Why?
| | Chemoembolization, Therapeutic | 1 | 2021 | 88 | 0.160 |
Why?
| | Kaplan-Meier Estimate | 5 | 2017 | 959 | 0.160 |
Why?
| | Smoking | 3 | 2024 | 1478 | 0.160 |
Why?
| | Patient Outcome Assessment | 1 | 2021 | 128 | 0.160 |
Why?
| | Chemokine CX3CL1 | 1 | 2020 | 25 | 0.150 |
Why?
| | Immunohistochemistry | 3 | 2019 | 1709 | 0.150 |
Why?
| | Disease Models, Animal | 1 | 2010 | 4565 | 0.150 |
Why?
| | Survival Analysis | 3 | 2012 | 1372 | 0.150 |
Why?
| | Models, Organizational | 1 | 2020 | 145 | 0.150 |
Why?
| | Disease Management | 4 | 2018 | 649 | 0.150 |
Why?
| | Myositis, Inclusion Body | 1 | 2019 | 11 | 0.150 |
Why?
| | Graft Rejection | 2 | 2020 | 504 | 0.150 |
Why?
| | Radiography | 2 | 2011 | 856 | 0.140 |
Why?
| | Wnt-5a Protein | 1 | 2018 | 25 | 0.140 |
Why?
| | Gain of Function Mutation | 1 | 2018 | 35 | 0.140 |
Why?
| | Body Weight | 1 | 2022 | 964 | 0.140 |
Why?
| | Immunity, Innate | 1 | 2024 | 843 | 0.140 |
Why?
| | Ambulatory Care Facilities | 1 | 2020 | 267 | 0.130 |
Why?
| | Hypoxia | 1 | 2025 | 1209 | 0.130 |
Why?
| | Signal Transduction | 2 | 2023 | 5234 | 0.130 |
Why?
| | Focus Groups | 2 | 2020 | 587 | 0.130 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2024 | 1754 | 0.130 |
Why?
| | International Cooperation | 1 | 2017 | 192 | 0.120 |
Why?
| | Myofibroblasts | 1 | 2018 | 149 | 0.120 |
Why?
| | Weight Loss | 1 | 2022 | 857 | 0.120 |
Why?
| | Amino Acyl-tRNA Synthetases | 1 | 2016 | 32 | 0.120 |
Why?
| | Health Status Indicators | 1 | 2017 | 166 | 0.120 |
Why?
| | Women's Health | 1 | 2018 | 317 | 0.120 |
Why?
| | Patient-Centered Care | 1 | 2021 | 551 | 0.120 |
Why?
| | Extracellular Vesicles | 1 | 2018 | 175 | 0.120 |
Why?
| | Tomography Scanners, X-Ray Computed | 1 | 2015 | 21 | 0.110 |
Why?
| | Practice Patterns, Physicians' | 1 | 2025 | 1370 | 0.110 |
Why?
| | Acute Disease | 3 | 2016 | 1033 | 0.110 |
Why?
| | Follow-Up Studies | 4 | 2019 | 5397 | 0.110 |
Why?
| | Sarcoidosis | 1 | 2017 | 164 | 0.110 |
Why?
| | Cause of Death | 1 | 2017 | 455 | 0.110 |
Why?
| | Pulmonary Medicine | 1 | 2015 | 78 | 0.110 |
Why?
| | Antibiotic Prophylaxis | 1 | 2016 | 133 | 0.110 |
Why?
| | Sleep Wake Disorders | 1 | 2018 | 314 | 0.100 |
Why?
| | Nails | 1 | 2014 | 14 | 0.100 |
Why?
| | Hyperpigmentation | 1 | 2014 | 26 | 0.100 |
Why?
| | Hospitalization | 1 | 2025 | 2468 | 0.100 |
Why?
| | Bronchodilator Agents | 1 | 2015 | 186 | 0.100 |
Why?
| | Body Mass Index | 1 | 2022 | 2446 | 0.100 |
Why?
| | Laparoscopy | 1 | 2018 | 474 | 0.100 |
Why?
| | Oxygen Inhalation Therapy | 1 | 2016 | 189 | 0.100 |
Why?
| | Gene Expression Profiling | 1 | 2020 | 1790 | 0.100 |
Why?
| | Arsenic | 1 | 2014 | 66 | 0.100 |
Why?
| | Interleukin-13 | 1 | 2014 | 149 | 0.100 |
Why?
| | Age Factors | 3 | 2019 | 3321 | 0.100 |
Why?
| | Diagnostic Imaging | 1 | 2016 | 340 | 0.100 |
Why?
| | Keratin-18 | 1 | 2012 | 12 | 0.090 |
Why?
| | Counseling | 1 | 2016 | 403 | 0.090 |
Why?
| | Cystic Fibrosis | 1 | 2023 | 1164 | 0.090 |
Why?
| | Autoimmunity | 2 | 2015 | 924 | 0.090 |
Why?
| | Maternal Exposure | 1 | 2014 | 189 | 0.090 |
Why?
| | Mass Screening | 3 | 2026 | 1300 | 0.090 |
Why?
| | Microspheres | 2 | 2023 | 142 | 0.090 |
Why?
| | Interviews as Topic | 1 | 2016 | 926 | 0.090 |
Why?
| | Sjogren's Syndrome | 2 | 2024 | 31 | 0.090 |
Why?
| | Fatigue | 1 | 2014 | 362 | 0.090 |
Why?
| | Age Distribution | 3 | 2019 | 395 | 0.090 |
Why?
| | Time Factors | 2 | 2024 | 7079 | 0.080 |
Why?
| | Dermatitis, Atopic | 1 | 2014 | 319 | 0.080 |
Why?
| | Algorithms | 2 | 2016 | 1843 | 0.080 |
Why?
| | Everolimus | 1 | 2011 | 112 | 0.080 |
Why?
| | Epithelial Cells | 2 | 2014 | 1118 | 0.080 |
Why?
| | Programmed Cell Death 1 Receptor | 2 | 2023 | 268 | 0.080 |
Why?
| | Sodium-Potassium-Exchanging ATPase | 1 | 2010 | 55 | 0.080 |
Why?
| | Tumor Microenvironment | 2 | 2025 | 745 | 0.080 |
Why?
| | Animals | 7 | 2025 | 38030 | 0.080 |
Why?
| | Goals | 1 | 2011 | 187 | 0.080 |
Why?
| | Fetus | 1 | 2014 | 798 | 0.070 |
Why?
| | Delphi Technique | 2 | 2022 | 347 | 0.070 |
Why?
| | Leukocytes | 2 | 2025 | 301 | 0.070 |
Why?
| | Alveolar Epithelial Cells | 1 | 2010 | 121 | 0.070 |
Why?
| | Health Status | 1 | 2014 | 822 | 0.070 |
Why?
| | Singapore | 2 | 2021 | 27 | 0.070 |
Why?
| | Sensitivity and Specificity | 1 | 2013 | 1992 | 0.070 |
Why?
| | Virus Diseases | 1 | 2011 | 219 | 0.070 |
Why?
| | Qualitative Research | 1 | 2016 | 1720 | 0.070 |
Why?
| | Syndrome | 2 | 2022 | 377 | 0.070 |
Why?
| | Models, Statistical | 1 | 2012 | 667 | 0.070 |
Why?
| | Proto-Oncogene Proteins c-akt | 1 | 2010 | 438 | 0.070 |
Why?
| | DNA | 1 | 2014 | 1418 | 0.060 |
Why?
| | Multivariate Analysis | 2 | 2025 | 1531 | 0.060 |
Why?
| | Pulmonary Alveoli | 2 | 2025 | 385 | 0.060 |
Why?
| | Antibodies, Monoclonal | 1 | 2014 | 1511 | 0.060 |
Why?
| | Micelles | 1 | 2026 | 37 | 0.060 |
Why?
| | Cell Membrane | 1 | 2010 | 701 | 0.060 |
Why?
| | Internationality | 2 | 2017 | 156 | 0.060 |
Why?
| | Japan | 1 | 2026 | 149 | 0.060 |
Why?
| | France | 1 | 2025 | 40 | 0.060 |
Why?
| | Pulmonary Surfactant-Associated Protein D | 1 | 2025 | 31 | 0.060 |
Why?
| | Promoter Regions, Genetic | 2 | 2021 | 1236 | 0.060 |
Why?
| | Logistic Models | 2 | 2025 | 2112 | 0.050 |
Why?
| | Methotrexate | 2 | 2021 | 234 | 0.050 |
Why?
| | Genetic Loci | 1 | 2026 | 272 | 0.050 |
Why?
| | Cyclophosphamide | 1 | 2025 | 275 | 0.050 |
Why?
| | Mixed Connective Tissue Disease | 1 | 2024 | 10 | 0.050 |
Why?
| | Pandemics | 2 | 2024 | 1700 | 0.050 |
Why?
| | Prednisone | 2 | 2019 | 229 | 0.050 |
Why?
| | Sex Distribution | 2 | 2015 | 379 | 0.050 |
Why?
| | Mice | 3 | 2025 | 18266 | 0.050 |
Why?
| | Demography | 1 | 2024 | 274 | 0.050 |
Why?
| | Professional Practice Gaps | 1 | 2023 | 15 | 0.050 |
Why?
| | Chromosome Deletion | 1 | 2023 | 126 | 0.050 |
Why?
| | Adaptive Immunity | 1 | 2024 | 172 | 0.050 |
Why?
| | CD3 Complex | 1 | 2023 | 112 | 0.050 |
Why?
| | Agent Orange | 1 | 2022 | 3 | 0.050 |
Why?
| | 2,4,5-Trichlorophenoxyacetic Acid | 1 | 2022 | 3 | 0.050 |
Why?
| | 2,4-Dichlorophenoxyacetic Acid | 1 | 2022 | 14 | 0.050 |
Why?
| | Palliative Care | 1 | 2011 | 1032 | 0.050 |
Why?
| | CTLA-4 Antigen | 1 | 2023 | 105 | 0.050 |
Why?
| | Antibody Formation | 1 | 2024 | 290 | 0.050 |
Why?
| | Whole Genome Sequencing | 1 | 2023 | 183 | 0.040 |
Why?
| | Respiratory Mucosa | 1 | 2025 | 323 | 0.040 |
Why?
| | Exome | 1 | 2023 | 232 | 0.040 |
Why?
| | Probability | 1 | 2022 | 308 | 0.040 |
Why?
| | Patient Reported Outcome Measures | 1 | 2025 | 502 | 0.040 |
Why?
| | Administration, Intravenous | 1 | 2021 | 172 | 0.040 |
Why?
| | Double-Blind Method | 1 | 2025 | 2064 | 0.040 |
Why?
| | Evidence-Based Medicine | 1 | 2024 | 727 | 0.040 |
Why?
| | Family | 1 | 2025 | 680 | 0.040 |
Why?
| | Bayes Theorem | 1 | 2022 | 424 | 0.040 |
Why?
| | CX3C Chemokine Receptor 1 | 1 | 2020 | 19 | 0.040 |
Why?
| | Leukocytes, Mononuclear | 1 | 2023 | 585 | 0.040 |
Why?
| | Total Lung Capacity | 1 | 2019 | 29 | 0.040 |
Why?
| | Pilot Projects | 1 | 2025 | 1878 | 0.040 |
Why?
| | Immunologic Factors | 1 | 2022 | 244 | 0.040 |
Why?
| | Allografts | 1 | 2020 | 148 | 0.040 |
Why?
| | Drug Discovery | 1 | 2020 | 153 | 0.040 |
Why?
| | Antibodies, Viral | 1 | 2024 | 683 | 0.040 |
Why?
| | Safety | 1 | 2021 | 346 | 0.040 |
Why?
| | Mice, Inbred C57BL | 1 | 2010 | 6021 | 0.040 |
Why?
| | Cross-Sectional Studies | 2 | 2025 | 5875 | 0.040 |
Why?
| | Fibroblasts | 1 | 2025 | 1033 | 0.040 |
Why?
| | Ireland | 1 | 2019 | 33 | 0.040 |
Why?
| | Genome-Wide Association Study | 1 | 2026 | 1526 | 0.040 |
Why?
| | Embolization, Therapeutic | 1 | 2021 | 246 | 0.040 |
Why?
| | Dermatomyositis | 1 | 2019 | 24 | 0.040 |
Why?
| | Insulin | 1 | 2010 | 2524 | 0.040 |
Why?
| | Echocardiography | 1 | 2022 | 645 | 0.030 |
Why?
| | Rare Diseases | 1 | 2019 | 115 | 0.030 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2026 | 2228 | 0.030 |
Why?
| | Combined Modality Therapy | 1 | 2021 | 1269 | 0.030 |
Why?
| | Hydrogen-Ion Concentration | 1 | 2020 | 533 | 0.030 |
Why?
| | Intention to Treat Analysis | 1 | 2018 | 78 | 0.030 |
Why?
| | National Heart, Lung, and Blood Institute (U.S.) | 1 | 2018 | 103 | 0.030 |
Why?
| | Education | 1 | 2018 | 102 | 0.030 |
Why?
| | Behavior | 1 | 2018 | 90 | 0.030 |
Why?
| | Morbidity | 1 | 2018 | 317 | 0.030 |
Why?
| | United Kingdom | 1 | 2019 | 376 | 0.030 |
Why?
| | Sleep Apnea Syndromes | 1 | 2018 | 98 | 0.030 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2023 | 929 | 0.030 |
Why?
| | Medicare | 1 | 2023 | 907 | 0.030 |
Why?
| | Comprehension | 1 | 2018 | 175 | 0.030 |
Why?
| | Linear Models | 1 | 2019 | 847 | 0.030 |
Why?
| | Registries | 1 | 2025 | 2382 | 0.030 |
Why?
| | Antibodies, Antinuclear | 1 | 2016 | 60 | 0.030 |
Why?
| | Muscle Strength | 1 | 2019 | 332 | 0.030 |
Why?
| | Flow Cytometry | 1 | 2020 | 1160 | 0.030 |
Why?
| | Odds Ratio | 1 | 2018 | 1070 | 0.030 |
Why?
| | Gene Expression | 1 | 2020 | 1461 | 0.030 |
Why?
| | California | 1 | 2017 | 473 | 0.030 |
Why?
| | Evaluation Studies as Topic | 1 | 2015 | 160 | 0.030 |
Why?
| | Global Health | 1 | 2018 | 402 | 0.030 |
Why?
| | Monitoring, Physiologic | 1 | 2017 | 278 | 0.030 |
Why?
| | Pneumonia, Aspiration | 1 | 2015 | 16 | 0.030 |
Why?
| | Vaccination | 1 | 2024 | 1444 | 0.030 |
Why?
| | Bronchiolitis Obliterans | 1 | 2015 | 59 | 0.030 |
Why?
| | Recovery of Function | 1 | 2019 | 721 | 0.030 |
Why?
| | Regression Analysis | 1 | 2017 | 994 | 0.030 |
Why?
| | Sampling Studies | 1 | 2014 | 97 | 0.030 |
Why?
| | San Francisco | 1 | 2014 | 60 | 0.030 |
Why?
| | Chicago | 1 | 2014 | 62 | 0.030 |
Why?
| | Europe | 1 | 2015 | 420 | 0.030 |
Why?
| | Neck | 1 | 2014 | 107 | 0.030 |
Why?
| | Patient Acuity | 1 | 2013 | 46 | 0.020 |
Why?
| | Endothelial Cells | 1 | 2020 | 876 | 0.020 |
Why?
| | Texas | 1 | 2014 | 279 | 0.020 |
Why?
| | Mice, SCID | 1 | 2014 | 360 | 0.020 |
Why?
| | Observational Studies as Topic | 1 | 2013 | 133 | 0.020 |
Why?
| | Enzyme Inhibitors | 1 | 2016 | 820 | 0.020 |
Why?
| | Protein Kinase Inhibitors | 1 | 2019 | 982 | 0.020 |
Why?
| | Developing Countries | 1 | 2014 | 312 | 0.020 |
Why?
| | Surveys and Questionnaires | 1 | 2025 | 6050 | 0.020 |
Why?
| | Young Adult | 2 | 2022 | 14240 | 0.020 |
Why?
| | Endoplasmic Reticulum Stress | 1 | 2012 | 120 | 0.020 |
Why?
| | Torque teno virus | 1 | 2011 | 1 | 0.020 |
Why?
| | DNA Virus Infections | 1 | 2011 | 3 | 0.020 |
Why?
| | Up-Regulation | 1 | 2014 | 840 | 0.020 |
Why?
| | Cells, Cultured | 1 | 2018 | 4112 | 0.020 |
Why?
| | Academic Medical Centers | 1 | 2014 | 560 | 0.020 |
Why?
| | Molecular Targeted Therapy | 1 | 2014 | 446 | 0.020 |
Why?
| | Mass Spectrometry | 1 | 2014 | 728 | 0.020 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 1 | 2018 | 926 | 0.020 |
Why?
| | Microarray Analysis | 1 | 2011 | 117 | 0.020 |
Why?
| | Models, Theoretical | 1 | 2014 | 558 | 0.020 |
Why?
| | Colorado | 1 | 2020 | 4588 | 0.020 |
Why?
| | Subcellular Fractions | 1 | 2010 | 73 | 0.020 |
Why?
| | GTPase-Activating Proteins | 1 | 2010 | 81 | 0.020 |
Why?
| | Body Fluids | 1 | 2010 | 70 | 0.020 |
Why?
| | Practice Guidelines as Topic | 1 | 2017 | 1581 | 0.020 |
Why?
| | rab GTP-Binding Proteins | 1 | 2010 | 76 | 0.020 |
Why?
| | Adolescent | 2 | 2022 | 22451 | 0.020 |
Why?
| | Reproducibility of Results | 1 | 2017 | 3396 | 0.020 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2011 | 751 | 0.020 |
Why?
| | Inflammation | 1 | 2020 | 2915 | 0.020 |
Why?
| | Models, Biological | 1 | 2016 | 1758 | 0.020 |
Why?
| | Protein Transport | 1 | 2010 | 439 | 0.020 |
Why?
| | Sequence Analysis, DNA | 1 | 2011 | 771 | 0.020 |
Why?
| | Polymerase Chain Reaction | 1 | 2011 | 1030 | 0.020 |
Why?
| | Phosphatidylinositol 3-Kinases | 1 | 2010 | 384 | 0.020 |
Why?
| | Telemedicine | 1 | 2017 | 956 | 0.020 |
Why?
| | Cattle | 1 | 2010 | 938 | 0.020 |
Why?
| | Asthma | 1 | 2018 | 1800 | 0.020 |
Why?
| | Respiratory Tract Infections | 1 | 2011 | 399 | 0.010 |
Why?
| | Rats, Sprague-Dawley | 1 | 2010 | 2533 | 0.010 |
Why?
| | Apoptosis | 1 | 2012 | 2436 | 0.010 |
Why?
| | Rats | 1 | 2010 | 5574 | 0.010 |
Why?
| | Pregnancy | 1 | 2014 | 7217 | 0.010 |
Why?
| | Infant | 1 | 2014 | 10093 | 0.010 |
Why?
| | Child | 1 | 2014 | 22638 | 0.010 |
Why?
|
|
Lee's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|